Literature DB >> 31251827

hnRNPM, a potential mediator of YY1 in promoting the epithelial-mesenchymal transition of prostate cancer cells.

Tong Yang1, Zesheng An1, Changwen Zhang1, Zhen Wang1, Xiaoming Wang1, Yan Liu1, E Du1, Ranlu Liu1, Zhihong Zhang1, Yong Xu1.   

Abstract

BACKGROUND: With the popularity of serum prostate-specific antigen (PSA) screening, the number of newly diagnosed prostate cancer (PCa) patients is increasing. However, indolent or invasive PCa cannot be distinguished by PSA levels. Here, we mainly explored the role of heterogeneous nuclear ribonucleoprotein M (hnRNPM) in the invasiveness of PCa.
METHODS: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blot analysis was used to detect the expressions of hnRNPM in PCa and benign prostate hyperplasia (BPH) tissues as well as in PCa cell lines. Immunohistochemistry was applied to detect the hnRNPM or Yin Yang 1 (YY1) expression in BPH, prostate adenocarcinoma (ADENO) and neuroendocrine prostate cancer (NEPC) tissues. After aberrant, the expression of hnRNPM in C4-2 and PC3 cells, the changes of cell migration and invasion were observed through wound-healing and transwell assays. We also predicted the transcription factor of hnRNPM through databases, then verified the association of hnRNPM and YY1 using chromatin immunoprecipitation (ChIP) and luciferase assays.
RESULTS: The expression level of hnRNPM is gradually reduced in BPH, ADENO, and NEPC tissues and it is less expressed in more aggressive PCa cell lines. Overexpression of hnRNPM can significantly reduce Twist1 expression, which inhibits the migration and invasion of PCa cells in vitro. In PCa cells, overexpression of YY1 can promote epithelial-mesenchymal transition by reducing hnRNPM expression. Furthermore, this effect caused by overexpression of YY1 can be partially attenuated by simultaneous overexpression of hnRNPM.
CONCLUSIONS: Our study demonstrates that hnRNPM negatively regulated PCa cell migration and invasion, and its expression can be transcriptionally inhibited by YY1. We speculated that hnRNPM may be a biomarker to assist in judging the aggressiveness of PCa.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  YY1; epithelial-mesenchymal transition; heterogeneous nuclear ribonucleoprotein M; prostate cancer

Year:  2019        PMID: 31251827     DOI: 10.1002/pros.23790

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  10 in total

1.  Protein signatures to distinguish aggressive from indolent prostate cancer.

Authors:  Fernando Garcia-Marques; Shiqin Liu; Sarah M Totten; Abel Bermudez; Cheylene Tanimoto; En-Chi Hsu; Rosalie Nolley; Amy Hembree; Tanya Stoyanova; James D Brooks; Sharon J Pitteri
Journal:  Prostate       Date:  2022-01-31       Impact factor: 4.104

2.  SILAC kinase screen identifies potential MASTL substrates.

Authors:  Kamila A Marzec; Samuel Rogers; Rachael McCloy; Benjamin L Parker; David E James; D Neil Watkins; Andrew Burgess
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

3.  YY1-mediated reticulocalbin-2 upregulation promotes the hepatocellular carcinoma progression via activating MYC signaling.

Authors:  Chengjie Mei; Xiang Jiang; Yang Gu; Xiaoling Wu; Weijie Ma; Xi Chen; Ganggang Wang; Ye Yao; Yingyi Liu; Zhonglin Zhang; Yufeng Yuan
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

4.  Characterization of HMGB1/2 Interactome in Prostate Cancer by Yeast Two Hybrid Approach: Potential Pathobiological Implications.

Authors:  Aida Barreiro-Alonso; María Cámara-Quílez; Martín Salamini-Montemurri; Mónica Lamas-Maceiras; Ángel Vizoso-Vázquez; Esther Rodríguez-Belmonte; María Quindós-Varela; Olaia Martínez-Iglesias; Angélica Figueroa; María-Esperanza Cerdán
Journal:  Cancers (Basel)       Date:  2019-11-05       Impact factor: 6.639

5.  HOXD3 was negatively regulated by YY1 recruiting HDAC1 to suppress progression of hepatocellular carcinoma cells via ITGA2 pathway.

Authors:  Lumin Wang; Yi Gao; Xiaoge Zhao; Chen Guo; Xiaofei Wang; Yang Yang; Cong Han; Lingyu Zhao; Yannan Qin; Liying Liu; Chen Huang; Wenjing Wang
Journal:  Cell Prolif       Date:  2020-06-17       Impact factor: 6.831

6.  Alterations in Glucose Metabolism Due to Decreased Expression of Heterogeneous Nuclear Ribonucleoprotein M in Pancreatic Ductal Adenocarcinoma.

Authors:  Jun-Ichi Takino; Takuma Sato; Isamu Hiraishi; Kentaro Nagamine; Takamitsu Hori
Journal:  Biology (Basel)       Date:  2021-01-14

7.  Downregulation of HNRNPM inhibits cell proliferation and migration of hepatocellular carcinoma through MAPK/AKT signaling pathway.

Authors:  Lu Qiao; Ning Xie; Yan Li; Yuru Bai; Na Liu; Jinhai Wang
Journal:  Transl Cancer Res       Date:  2022-07       Impact factor: 0.496

Review 8.  The Two Sides of YY1 in Cancer: A Friend and a Foe.

Authors:  Sailu Sarvagalla; Srinivasa Prasad Kolapalli; Sivakumar Vallabhapurapu
Journal:  Front Oncol       Date:  2019-11-20       Impact factor: 6.244

Review 9.  The biological implications of Yin Yang 1 in the hallmarks of cancer.

Authors:  Ian Timothy Sembiring Meliala; Rendy Hosea; Vivi Kasim; Shourong Wu
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

10.  Pan-cancer analysis of alternative splicing regulator heterogeneous nuclear ribonucleoproteins (hnRNPs) family and their prognostic potential.

Authors:  Hao Li; Jingwei Liu; Shixuan Shen; Di Dai; Shitong Cheng; Xiaolong Dong; Liping Sun; Xiaolin Guo
Journal:  J Cell Mol Med       Date:  2020-09-11       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.